{"url_path":"/sec/rgbpp/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1589150/0001493152-26-022924-index.html","accession_number":"0001493152-26-022924","cik":"0001589150","ticker":"RGBP","issuer_name":"Regen BioPharma Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1589150/0001493152-26-022924-index.html","primary_entity_key":"0001589150","primary_entity_name":"Regen BioPharma Inc"},"word_count":270,"has_tables":true,"body_markdown":"**Item\n2. Unregistered Sales of Equity Securities and Use of Proceeds**\n\n** **\n\nDuring\nthe period beginning January 1 2026 and ending March 31, 2026 the Company issued an aggregate of 232,272,777 Common Shares (“Shares”)\nin satisfaction of $138,072 of principal convertible indebtedness, $13,630 of accrued interest on convertible indebtedness and $20,500\nin incurred fees.\n\n \n\nThe\nShares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended (the “Act”). No underwriters were\nretained to serve as placement agents for the sale. The shares were sold directly through our management. No commission or other consideration\nwas paid in connection with the sale of the shares. There was no advertisement or general solicitation made in connection with this Offer\nand Sale of Shares.\n\n \n\nOn\nJanuary 30, 2026 the Company issued 11,111,111 common shares (“Shares”) for consideration consisting of $50,000.\n\n \n\nThe\nShares were issued pursuant to a Tier 2 Regulation A Offering. The Shares were sold directly through our management.\n\n \n\nBetween\nApril 14th 2026 and April 28th 2026 the Company issued an aggregate of 160,519, 051 common shares (“Shares”) in satisfaction\nof $37,489 of principal convertible indebtedness, $857 of accrued interest on convertible indebtedness and $3,000 in incurred fees.\n\n \n\nThe\nShares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended (the “Act”). No underwriters were\nretained to serve as placement agents for the sale. The shares were sold directly through our management. No commission or other consideration\nwas paid in connection with the sale of the shares. There was no advertisement or general solicitation made in connection with this Offer\nand Sale of Shares."}